AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports
December 03, 2019 08:32 ET | AZTherapies, Inc.
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS Company expects to advance its re-engineered inhaled cromolyn candidate AZT-101...
download.jpg
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
November 25, 2019 06:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
October 04, 2019 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
September 26, 2019 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in...
retro.jpg
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
July 19, 2019 11:15 ET | Retrotope
LOS ALTOS, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it closed a Series C financing, enabling expansion of its pipeline of novel first-in-class drugs called D-PUFAs...
logo.png
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
July 18, 2019 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No. 17/2019                                         ...
Foundation Fighting Blindness Appoints Judy Taylor Vice President, Development
July 15, 2019 10:00 ET | Foundation Fighting Blindness
Columbia, MD, July 15, 2019 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness, the world’s leading private funding source for retinal degenerative disease research, has announced that it has...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 30, 2019 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 30, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in...
retro.jpg
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 06, 2019 12:57 ET | Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
Biogen_Logo_Standard-rgb_R.jpg
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
May 01, 2019 16:30 ET | Biogen Inc.
Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase...